ADP-ribosylation-resistant Rifabutin Analogs Show Improved Bactericidal Activity Against Drug-tolerant in Caseum Surrogate

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2023 Jul 26

PMID 37493373

Authors

Min Xie

Uday S Ganapathy

Tian Lan

Paulina Osiecki

Jansy P Sarathy

Veronique Dartois

Courtney C Aldrich

Thomas Dick

Affiliations

Soon will be listed here.

Abstract

Necrotic lesions and cavities filled with caseum are a hallmark of mycobacterial pulmonary disease. Bronchocavitary disease is associated with poor treatment outcomes. In caseum surrogate, entered an extended stationary phase showing tolerance to killing by most current antibiotics, suggesting that caseum persisters contribute to the poor performance of available treatments. Novel ADP-ribosylation-resistant rifabutin analogs exhibited bactericidal activity against these persisters at concentrations achievable by rifamycins in caseum.

Citing Articles

A Physiologically Relevant In Vitro Model of Nonreplicating Persistent Mycobacterium tuberculosis in Caseum.

Xie M, Osiecki P, Rodriguez S, Dartois V, Sarathy J Curr Protoc. 2025; 5(3):e70118.

PMID: 40056090 PMC: 11890023. DOI: 10.1002/cpz1.70118.

Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.

Negatu D, Aragaw W, Gebresilase T, Paruchuri S, Kaya F, Shin S Antimicrob Agents Chemother. 2024; 69(1):e0104624.

PMID: 39565116 PMC: 11784023. DOI: 10.1128/aac.01046-24.

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of .

Aragaw W, Gebresilase T, Negatu D, Dartois V, Dick T Antimicrob Agents Chemother. 2024; 68(12):e0105124.

PMID: 39470195 PMC: 11619451. DOI: 10.1128/aac.01051-24.

Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.

Sarathy J PLoS Pathog. 2024; 20(10):e1012595.

PMID: 39383167 PMC: 11463790. DOI: 10.1371/journal.ppat.1012595.

Toward better cures for lung disease.

Dartois V, Dick T Clin Microbiol Rev. 2024; 37(4):e0008023.

PMID: 39360834 PMC: 11629636. DOI: 10.1128/cmr.00080-23.

References

Aziz D, Low J, Wu M, Gengenbacher M, Teo J, Dartois V . Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444174. DOI: 10.1128/AAC.00155-17. View

Ganapathy U, Lan T, Krastel P, Lindman M, Zimmerman M, Ho H . Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus. Antimicrob Agents Chemother. 2021; 65(9):e0097821. PMC: 8370238. DOI: 10.1128/AAC.00978-21. View

Strydom N, Gupta S, Fox W, Via L, Bang H, Lee M . Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019; 16(4):e1002773. PMC: 6445413. DOI: 10.1371/journal.pmed.1002773. View

Kaya F, Ernest J, LoMauro K, Gengenbacher M, Madani A, Aragaw W . A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. Antimicrob Agents Chemother. 2022; 66(3):e0221221. PMC: 8923217. DOI: 10.1128/aac.02212-21. View

Irwin S, Prideaux B, Lyon E, Zimmerman M, Brooks E, Schrupp C . Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Infected C3HeB/FeJ Mice. ACS Infect Dis. 2016; 2(4):251-267. PMC: 4874602. DOI: 10.1021/acsinfecdis.5b00127. View

Sarathy J, Ganapathy U, Zimmerman M, Dartois V, Gengenbacher M, Dick T . TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother. 2020; 64(4). PMC: 7179298. DOI: 10.1128/AAC.02404-19. View

Schafle D, Selchow P, Borer B, Meuli M, Rominski A, Schulthess B . Rifabutin Is Inactivated by Mycobacterium abscessus Arr. Antimicrob Agents Chemother. 2020; 65(3). PMC: 8092531. DOI: 10.1128/AAC.02215-20. View

Rominski A, Roditscheff A, Selchow P, Bottger E, Sander P . Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother. 2016; 72(2):376-384. DOI: 10.1093/jac/dkw466. View

Ganapathy U, Gonzalez Del Rio R, Cacho-Izquierdo M, Ortega F, Lelievre J, Barros-Aguirre D . A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother. 2021; 65(12):e0151421. PMC: 8597734. DOI: 10.1128/AAC.01514-21. View

10.

Lan T, Ganapathy U, Sharma S, Ahn Y, Zimmerman M, Molodtsov V . Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance. Angew Chem Int Ed Engl. 2022; 61(45):e202211498. PMC: 9633546. DOI: 10.1002/anie.202211498. View

11.

Fox W, Ellard G, Mitchison D . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999; 3(10 Suppl 2):S231-79. View

12.

Sarathy J, Via L, Weiner D, Blanc L, Boshoff H, Eugenin E . Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786764. DOI: 10.1128/AAC.02266-17. View

13.

Dhillon J, Andries K, Phillips P, Mitchison D . Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb). 2010; 90(5):301-5. DOI: 10.1016/j.tube.2010.07.004. View

14.

Griffith D, Daley C . Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2021; 161(1):64-75. DOI: 10.1016/j.chest.2021.07.035. View

15.

Negatu D, Beuchel A, Madani A, Alvarez N, Chen C, Aragaw W . Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrob Agents Chemother. 2021; 65(8):e0067621. PMC: 8284461. DOI: 10.1128/AAC.00676-21. View

16.

Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K . Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008; 283(37):25273-25280. DOI: 10.1074/jbc.M803899200. View

17.

Sarathy J, Dartois V . Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters. Clin Microbiol Rev. 2020; 33(3). PMC: 7117546. DOI: 10.1128/CMR.00159-19. View

18.

Yee M, Klinzing D, Wei J, Gengenbacher M, Rubin E, Dick T . Draft Genome Sequence of Bamboo. Genome Announc. 2017; 5(20). PMC: 5477336. DOI: 10.1128/genomeA.00388-17. View

19.

Ganapathy U, Gonzalez Del Rio R, Cacho-Izquierdo M, Ortega F, Lelievre J, Barros-Aguirre D . A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity. Antimicrob Agents Chemother. 2021; 95(5). PMC: 8092876. DOI: 10.1128/AAC.02420-20. View

20.

Dick T, Shin S, Koh W, Dartois V, Gengenbacher M . Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrob Agents Chemother. 2019; 64(2). PMC: 6985736. DOI: 10.1128/AAC.01943-19. View